Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Published byVegard Dale Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E"— Presentation transcript:

1 (A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
(A) Mean (SD) serum continuous erythropoietin receptor activator (C.E.R.A.) concentration and (B) mean (SD) reticulocyte count after intravenous (IV) and subcutaneous (SC) administration in peritoneal dialysis patients. (A) Mean (SD) serum continuous erythropoietin receptor activator (C.E.R.A.) concentration and (B) mean (SD) reticulocyte count after intravenous (IV) and subcutaneous (SC) administration in peritoneal dialysis patients. Iain C. Macdougall et al. CJASN 2006;1: ©2006 by American Society of Nephrology

Download ppt "(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E"

Similar presentations

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
New options for the anemia of chronic kidney disease

New options for the anemia of chronic kidney disease
Iron status and iron supplementation in peritoneal dialysis patients

Iron status and iron supplementation in peritoneal dialysis patients
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Protocol for management of adult patients with DKA or HHS

Protocol for management of adult patients with DKA or HHS
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Volume 62, Issue 2, Pages (August 2002)

Volume 62, Issue 2, Pages (August 2002)
Darbepoetin alfa: A new therapeutic agent for renal anemia

Darbepoetin alfa: A new therapeutic agent for renal anemia
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Francesco Locatelli, Lucia Del Vecchio  Kidney International 

Francesco Locatelli, Lucia Del Vecchio  Kidney International 
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.

Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)
Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Similar presentations

Ads by Google